About Event

What Can You Expect at the Premier Covalent Forum in 2026?

Returning for Its 4th Year, the Covalent Drug Discovery Summit Meets a Pivotal Moment

With covalent drug discovery moving from high-risk concept to clinically validated modality, the race is on to deliver safer, more selective, and translatable therapies.

The 4th Covalent Drug Discovery & Development Summit brings together industry leaders to share cutting-edge case studies and end-to-end development strategies.

Expect expert-led sessions, real-world translational insights, and meaningful networking designed to help you overcome selectivity and safety challenges, optimize discovery workflows, and confidently progress covalent candidates from design through to first-in-human studies.

Download the Agenda

Unmissable Event Highlights

Advance Precision Covalent Design Strategies

Discover how Dana-Farber, BMS, and Leiden University are expanding the covalent toolbox through novel warheads, non-cysteine targeting, and electrophile profiling. Learn how integrating structural biology and chemoproteomics is enhancing selectivity, optimizing reactivity, and enabling compounds to successfully progress through in vivo and IND-enabling stages.

Unlock New Biology with Covalent Modalities

Explore how Dana-Farber, Talus Bio, and Dunad Therapeutics are applying covalent strategies to transcription factors, deubiquitinases, and dynamic proteins. Learn how targeting novel residues and developing CNS-penetrant compounds are expanding beyond cysteine and classical inhibition to unlock previously undruggable biology.

Bridge the Gap from Discovery to First-in-Human

Gain end-to-end translational insights from Biogen, Lilly, and Antares Therapeutics. Explore how leading teams are integrating kinact/KI, PK/PD, and safety data to improve decision-making, guide dose selection, and de-risk progression, enabling more confident advancement of covalent candidates into early clinical trials.

Optimize Discovery with Next-Gen Screening & AI

Learn from BridGene, Frontier Medicines, Pfizer, and Axiom Therapeutics how advanced screening platforms, kinetic assays, and AI-driven modelling are transforming hit identification. Discover how proteome-wide approaches and integrated datasets are reducing off-target risk and accelerating high-confidence decision-making.